Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bahareh Nejad

Obstetrics & Gynecology Roseville, CA Medical Doctor

NPI 1811901176 CMS profile 699900

2261 Douglas Blvd, Roseville, CA 95661

Open in the dashboard

General payments

$138,566

207 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bahareh Nejad of Roseville, CA is reported in the CMS Open Payments database as having received $138,566 across 207 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $44,145 37
2024 General $28,697 47
2023 General $23,866 30
2022 General $14,677 23
2021 General $12,284 28
2020 General $9,275 10
2019 General $5,621 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bahareh Nejad
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Bahareh Nejad were reported at $44,145. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Bahareh Nejad Obstetrics & Gynecology median Middle half National median
2019 $5,621 $172 $62–$391 $163
2020 $9,275 $94 $36–$222 $114
2021 $12,284 $136 $42–$369 $132
2022 $14,677 $160 $50–$433 $149
2023 $23,866 $169 $56–$423 $160
2024 $28,697 $152 $50–$371 $164
2025 $44,145 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CONMED Corporation $85,715 59 payments
  2. Intuitive Surgical, Inc. $32,872 93 payments
  3. CooperSurgical, Inc. $17,279 22 payments
  4. Hologic, LLC $2,030 26 payments
  5. Acessa Health Inc. $236 1 payment
  6. Medtronic, Inc. $224 2 payments
  7. Covidien LP $179 2 payments
  8. Ethicon US, LLC $31 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $66,296 39 payments
  2. Travel and Lodging $42,095 57 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,550 13 payments
  4. Food and Beverage $9,916 91 payments
  5. Education $1,659 4 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $1,000 1 payment
  7. Gift $49 2 payments
Products named General payments · program years 2019–2025
  1. AIRSEAL $85,411 57 payments
  2. Da Vinci Surgical System $23,722 88 payments
  3. DA VINCI SP $9,150 5 payments
  4. Uterine Manipulators & Injectors Devices $5,750 5 payments
  5. Uterine Manipulators & Injectors Devices $4,633 4 payments
  6. ALLY II UPS $3,888 6 payments
  7. Advincula Delineator Uterine Manipulator $3,000 6 payments
  8. ACESSA PROVU SYSTEM Surgical $1,182 14 payments
  9. ACESSA PROVU SYSTEM Surgical $634 6 payments
  10. MYOSURE TISSUE REMOVAL DEVICE $559 6 payments
  11. Other $1,726 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

100

Median for Obstetrics & Gynecology: 65

Drug cost

$12,749

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

61%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vivelle-Dot Estradiol Brand 13 $4,624
Estradiol Generic 39 $4,157
Yuvafem Estradiol Brand 12 $2,518
Estradiol (Once Weekly) Estradiol Brand 25 $1,066
Progesterone Progesterone, Micronized Brand 11 $384

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$15,206

Medicare's payments for the services billed

Medicare patients

80

Average age 70

Services billed

151

80 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 49%
High blood pressure 45%
Depression 30%
Osteoporosis 24%
Diabetes 21%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

207 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record